Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
135 studies found for:    new onset type 1 diabetes
Show Display Options
Rank Status Study
21 Not yet recruiting Pilot Clinical Trial of Ustekinumab in Patients With New-onset T1D
Condition: Type 1 Diabetes
Intervention: Drug: Ustekinumab
22 Suspended A Research Trial of Aralast in New Onset Diabetes (RETAIN) - Part I
Condition: Diabetes Mellitus, Type 1
Interventions: Biological: Alpha 1-Antitrypsin;   Biological: Alpha-1 Antitrypsin
23 Recruiting Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus
Conditions: Diabetes Mellitus, Type I;   Diabetes Mellitus, Insulin-Dependent, 1;   Type 1 Diabetes Mellitus;   Insulin-Dependent Diabetes Mellitus 1;   IDDM
Interventions: Drug: Imatinib Mesylate;   Drug: Placebo (For imatinib mesylate)
24 Withdrawn A Research Trial of Aralast NP in New Onset Diabetes (RETAIN) - Part II
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Aralast NP;   Drug: Placebo
25 Not yet recruiting Tauroursodeoxycholic Acid (TUDCA) in New-Onset Type 1 Diabetes
Condition: Type 1 Diabetes
Interventions: Drug: Tauroursodeoxycholic Acid (TUDCA);   Drug: Sugar Pill (placebo)
26 Completed Etanercept in New Onset Type 1 Diabetes
Condition: Type 1 Diabetes
Interventions: Drug: Etanercept;   Drug: Placebo
27 Completed
Has Results
Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)
Condition: Type 1 Diabetes
Interventions: Drug: Atorvastatin;   Other: Placebo
28 Completed Effects of Rituximab on the Progression of Type 1 Diabetes in New Onset Subjects
Condition: Type 1 Diabetes Mellitus
Intervention: Drug: Anti-CD20 (rituximab)
29 Completed A Study of Two Versus Three Daily Injections in Children and Adolescents With Newly Diagnosed Type 1 Diabetes
Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Twice Daily versus Three Times Daily Insulin Injections
30 Completed
Has Results
Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes
Condition: Diabetes Mellitus, Type 1
Interventions: Biological: Anti-CD3 mAb;   Other: Diabetes Standard of Care Treatment;   Dietary Supplement: Iron supplementation
31 Unknown  New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Mycophenolate mofeteil (MMF);   Drug: Daclizumab (DZB)
32 Withdrawn A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody) Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus
Condition: New Onset Type 1 Diabetes Mellitus
Intervention: Drug: Campath 1H® (Alemtuzumab)
33 Completed Effects of Recombinant Human Glutamic Acid Decarboxylase . . .
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: GAD-Alum;   Drug: Aluminum hydroxide
34 Active, not recruiting Safety Study to Assess Whether Proinsulin Peptide Injections Can Slow or Stop the Body Damaging Its Own Insulin-making Cells in the Pancreas in Patients Newly Diagnosed With Type 1 Diabetes
Condition: Type 1 Diabetes
Interventions: Drug: Pro insulin peptide;   Drug: Saline
35 Terminated Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Secukinumab;   Drug: Placebo
36 Recruiting Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients
Condition: Diabetes Mellitus, Type 1
Interventions: Biological: Otelixizumab;   Biological: Placebo
37 Completed Prevalence of Vitamin D Deficiency in Type 1 Diabetes Mellitus and Effect on Insulin Requirements After Supplementation With Vitamin D
Condition: Type 1 Diabetes Mellitus
Intervention: Drug: Vitamin D
38 Not yet recruiting The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Lansoprazole for Insulin Independence Among Recent Onset Type 1 Diabetes Patients
Condition: Type 1 Diabetes
Interventions: Drug: Oral Cyclosporine A and Oral Lansoprazole;   Drug: Oral Placebos
39 Unknown  Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study
Condition: Diabetes Mellitus, Insulin-Dependent
Interventions: Biological: Diabetes-suppressive dendritic cell vaccine;   Biological: control dendritic cells
40 Recruiting Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"
Conditions: Autoantibody Positive;   Non-diabetic Relatives at Risk for Type 1 Diabetes;   High Risk;   Impaired Glucose Tolerance
Intervention: Drug: Teplizumab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years